PolyXen® product pipeline
| Partner |
Molecule |
Present Status |
Partnering Status |
| Serum Institute of India Ltd |
ErepoXen® - Polysialic erythropoietin |
Phase I |
Co-development |
| StimuXen™ - Granulocyte colony stimulating factor (polysialic G-CSF) |
Development/Preclinical |
Collaboration |
|
|
|
| Baxter |
Factor VIII** |
Development/Preclinical |
Collaboration |
| Genentech |
Cancer Compound** |
Development/Preclinical |
Collaboration |
| Amgen |
Undisclosed protein** |
Development/Preclinical |
Collaboration |
| Genzyme |
Undisclosed protein** |
Development/Preclinical |
Collaboration |
| In-House |
InferoXen® - Interferon a-2b |
Development/Preclinical |
Proprietary |
| In-House |
SuliXen® - Recombinant human insulin |
Phase I |
Proprietary |
|
* Collaboration for the co-development of product with shared rights. For other products with Serum Institute of India Ltd, Lipoxen retains rights to major market territories for all products except G-CSF, where rights are available for licensing.
** Proprietary to Partner |